Zogenix files for $86M initial public offering

Zogenix is testing the chilly public waters with an IPO filing designed to raise up to $86.25 million. Banc of America Securities, Leerink Swann, Thomas Weisel Partners, and Susquehanna Financial Group are listed as underwriters for the San Diego-based developer, which is backed by Domain Associates, Clarus Lifesciences, Scale Venture Partners, Thomas McNerney & Partners, Abingworth Bioventures.

Last week Zogenix announced that the FDA had accepted its NDA for sumatriptan DosePro for the acute treatment of migraine attacks. Zogenix has raised about $80 million in venture funds to date and is developing therapies for neurology and pain.

- check out this release
- read the report from Socaltech

Related Articles:
Zogenix sells stock. Report
Zogenix gains $60M in new VC funds. Report

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.